Who are Multi-strain probiotics's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): "AS-Probionorm", Ganeden BC30, Probiotic Vivomixx, Mesalazine plus Lactobacillus casei, Akkermansia muciniphila + Infliximab, Lactobacillus plantarum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/multi-strain-probiotics.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Multi-strain probiotics — Competitive Intelligence Brief

Multi-strain probiotics (Multi-strain probiotics) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

phase 3 Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Multi-strain probiotics (Multi-strain probiotics) — Seoul National University Hospital. Multi-strain probiotics restore and balance the gut microbiota to promote intestinal health and immune function.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Multi-strain probiotics TARGET	Multi-strain probiotics	Seoul National University Hospital	phase 3	Probiotic
"AS-Probionorm"	"AS-Probionorm"	Industrial Microbiology LLP	marketed	Probiotic
Ganeden BC30	Ganeden BC30	Massachusetts General Hospital	marketed	Probiotic
Probiotic Vivomixx	Probiotic Vivomixx	University of Milan	marketed	Probiotic
Mesalazine plus Lactobacillus casei	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)
Lactobacillus plantarum	Lactobacillus plantarum	Shenzhen People's Hospital	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Multi-strain probiotics — Competitive Intelligence Brief. https://druglandscape.com/ci/multi-strain-probiotics. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab